GGrantIndex
← Leaderboards

Judy Ellen Garber

Dana-Farber Cancer Institute

Google Scholar ↗PubMed ↗ORCID ↗
$7,881,827
Attributed
$13,570,720
Total exposure
12
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.2M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,145,116 · 13

By mechanism

R01$12,200,117 · 4
U19$10,574,396 · 1
P50$1,079,631 · 3
R21$257,125 · 1
M01$33,847 · 4

Top collaborators

Most similar at Dana-Farber Cancer Institute

Same institution · by research overlap

Others in their field

Top investigators on “Cancer Risk”

Research focus

Cancer RiskFemaleTumorMalignant Breast NeoplasmBreastResearch PersonnelGenesPhenotypeCohortInheritedExposure ToNext GenerationBreast NeoplasmsProgramsHuman SubjectMemberTranslational ResearchPrevalenceMolecularMutation CarrierGerm-Line MutationNeoplasmsGenotypeFamily

Grant awards (34)

Career Enhancement Program$136,675
P50 · FY2025 · CA · contact PI
Precision approaches to refining TP53-associated cancer risk$1,709,326
R01 · FY2023 · CA
Career Enhancement Program$165,056
P50 · FY2023 · CA · contact PI
Precision approaches to refining TP53-associated cancer risk$1,701,527
R01 · FY2022 · CA
Career Enhancement Program$157,500
P50 · FY2022 · CA · contact PI
Precision approaches to refining TP53-associated cancer risk$1,705,096
R01 · FY2021 · CA
Career Enhancement Program$177,837
P50 · FY2021 · CA · contact PI
Precision approaches to refining TP53-associated cancer risk$1,713,253
R01 · FY2020 · CA
Career Enhancement Program$166,722
P50 · FY2020 · CA · contact PI
Precision approaches to refining TP53-associated cancer risk$1,704,138
R01 · FY2019 · CA
Career Enhancement Program$275,841
P50 · FY2019 · CA · contact PI
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$574,120
U19 · FY2014 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,309,806
U19 · FY2013 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,486,910
U19 · FY2012 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,465,094
U19 · FY2011 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,738,466
U19 · FY2010 · CA
Epidemiology of Syndromic GI Stromal Tumors$449,094
R01 · FY2010 · CA · contact PI
Epidemiology of Syndromic GI Stromal Tumors$631,908
R01 · FY2009 · CA · contact PI
Epidemiology of Syndromic GI Stromal Tumors$631,925
R01 · FY2008 · CA · contact PI
PILOT STUDY OF AROMATASE INHIBITORS$1,915
M01 · FY2008 · RR · contact PI
Epidemiology of Syndromic GI Stromal Tumors$648,666
R01 · FY2007 · CA · contact PI
PILOT STUDY OF AROMATASE INHIBITORS$12,835
M01 · FY2007 · RR · contact PI
PILOT STUDY OF AROMATASE INHIBITORS$11,540
M01 · FY2006 · RR · contact PI
PILOT STUDY OF AROMATASE INHIBITORS$5,805
M01 · FY2005 · RR
Pilot Study of Aromatase Inhibitors$1,752
M01 · FY2004 · RR
Process &Outcomes of BRCAL/2 clinical testing$384,750
R01 · FY2003 · HG
Process &Outcomes of BRCAL/2 clinical testing$384,844
R01 · FY2002 · HG
BREAST CANCER PREVENTION IN HODGKINS DISEASE$128,375
R21 · FY2002 · CA
Plasma estrogens in breast cancer risk and prevention$0
P50 · FY2002 · CA
Process &Outcomes of BRCA1/2 clinical testing$385,969
R01 · FY2001 · HG
RANDOMIZED STUDY--BRCA1/2 GENETIC V CONSENT COUNSELING$149,621
R01 · FY2001 · HG
BREAST CANCER PREVENTION IN HODGKINS DISEASE$128,750
R21 · FY2001 · CA
Plasma estrogens in breast cancer risk and prevention$0
P50 · FY2001 · CA
Plasma estrogens in breast cancer risk and prevention$0
P50 · FY2000 · CA